Merck has entered a commercial supply agreement with US-based bluebird bio to manufacture viral vectors for gene therapies.
bluebird bio develops gene and cell therapies to treat severe genetic diseases and T-cell based immunotherapies for cancer.
Go deeper with GlobalData
The multi-year agreement involves Merck’s Life Science business sector, which will produce lentiviral vectors for bluebird bio’s products.
Viral vectors are used to deliver genes to immune cells to produce a therapeutic effect such as correction of a mutated gene.
Merck Life Science executive board member and CEO Udit Batra said: “We look forward to collaborating with bluebird bio to bring breakthrough therapies to fight diseases.
“With 30 years’ experience in viral vector manufacturing, we remain committed to innovating with academia, hospitals and cell therapy manufacturers to accelerate access to personalised cell therapy for the patients who need it most.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataMerck’s California-based facility has been focused on gene therapy since 1997, and provides manufacturing services for BioReliance viral and gene therapy.
The facility was recently expanded from 44,000ft2 to 65,000ft2 and currently includes 16 modular viral bulk manufacturing cleanroom suites, single-use equipment and two fill / finish suites for gene therapy, viral vaccine and immunotherapy products.
